Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907216 | 1.00 | HRH4 (0.45) | HRH4HRH3HRH2MAP4K1POLB | |
| SCHEMBL20135587 | 1.00 | HRH4 (0.45) | HRH4HRH3HRH2MAP4K1POLB | |
| Hydrochloric Acid SCHEMBL28549650 | 0.98 | ADRA2A (0.44) | HRH4HRH3HRH2MAP4K1POLB | |
| Hydrochloric Acid SCHEMBL28549653 | 0.98 | ADRA2A (0.44) | HRH4HRH3HRH2MAP4K1POLB | |
| SCHEMBL1460413 | 0.90 | HRH3 (0.49) | HRH3POLBMAPTRAB9AIRAK4 | |
| Bromide SCHEMBL1846722 | 0.89 | HRH3 (0.48) | HRH4HRH3POLBMAPTRAB9A | |
| Trifluoroacetic Acid SCHEMBL28545444 | 0.88 | HRH4 (0.60) | HRH4HRH3HRH2POLBMAPT | |
| Trifluoroacetic Acid SCHEMBL28545442 | 0.88 | HRH4 (0.60) | HRH4HRH3HRH2POLBMAPT | |
| SCHEMBL19633741 | 0.87 | RAB9A (0.49) | HRH3POLBMAPTRAB9ACCR6 | |
| SCHEMBL827867 | 0.81 | HCAR3 (0.56) | POLBMAPTRAB9ACCR6ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-05-06 | — | — | US | disclosed |
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| EP-2018381-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358958-B2 | — | CDK2, CDK1, CDK6 | HRH4 4083/4885HRH3 3213/4885HRH2 3930/4885 |
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | HRH4 90/4885HRH3 186/4885HRH2 118/4885 |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | HRH4 4367/4885HRH3 3293/4885HRH2 4207/4885 |
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | HRH4 4367/4885HRH3 3293/4885HRH2 4207/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | HRH4 448/4885HRH3 778/4885HRH2 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.